WHY BIOTECH STOCKS LIKE RECURSION PHARMACEUTICALS, CRISPR THERAPEUTICS, AND SUMMIT THERAPEUTICS PLUNGED TODAY
✍️ Biotech stocks Recursion Pharmaceuticals, Summit Therapeutics, and CRISPR Therapeutics plummeted on Monday due to a combination of factors, including a key resignation at the FDA and uncertainty about the approval process for new drug technologies.
👉 The resignation of Dr. Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research, has raised concerns about the speed and willingness of the FDA to approve new drug technologies.
👉 The FDA has approved 22 gene therapies during Marks' tenure, including treatments for inherited blindness, sickle cell anemia, and child leukemia.
👉 Recursion Pharmaceuticals, Summit Therapeutics, and CRISPR Therapeutics are all early-stage biotech companies working on next-generation therapeutics with advanced technologies.
👉 The companies' stocks fell 9.4%, 5.6%, and 9.2%, respectively, on Monday.
👉 The uncertainty surrounding the approval process has led to a sell-off in the biotech sector, with investors worried about the potential impact on the future revenue and profit outlook for these companies.
--
#Dr.PeterMarks #RobertF.KennedyJr. #SaraBrenner #ScottGottlieb #BillyDuberstein #FDA #WashingtonD.C. #health
